1. Kopyt N: Management and treatment of chronic kidney disease.
Nurse Pract 2007; 32: 14-23
2. Sidhu MS, Dellsperger KC: Cardiovascular problems in dialysis
patients: Impact on survival. Adv Perit Dial 2010; 26: 47-52
3. Weber C, Noels H: Atherosclerosis: Current pathogenesis and
therapeutic options. Nat Med 2011; 17: 1410-1422
4. Yılmaz MI, Çağlar K, Sağlam M, Eyileten T, Sonmez A, Açıkel C,
Özgürtaş T, Oğuz Y, Vural A, Yenicesu M: Endothelial dysfunction
in chronic renal disease; The role of adiponectin and infl ammation.
Turk Neph Dial Transpl 2007; 16(2): 54-62
5. Braunersreuther V, Mach F, Steffens S: The specifi c role of
chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-21
6. Wiley SR, Winkles JA: TWEAK, a member of the TNF superfamily,
is a multifunctional cytokine that binds the TWEAKR/Fn14
receptor. Cytokine Growth Factor Rev 2003; 14: 241–249
7. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS:
TWEAKing tissue remodeling by a multifunctional cytokine: Role
of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;
40: 1-16
8. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute
J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM: The
CD163-expressing macrophages recognize and internalize TWEAK:
Potential consequences in atherosclerosis. Atherosclerosis 2009;
207: 103-9. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M,
Desplat-Jego S, Chicheportiche Y, Dietrich PY: TWEAK stimulation
of astrocytes and the proinfl ammatory consequences. Glia 2000;
32(1): 102-107
10. Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J,
Ortiz A: Cytokine cooperation in renal tubular cell injury: The role
of TWEAK. Kidney Int 2006; 70: 1750-1758
11. Gao HX, Campbell SR, Burkly LC, Jakubowski A , Jarchum I,
Banas B, Saleem MA, Mathieson PW, Berman JW, Michaelson
JS, Putterman C: TNF-like weak inducer of apoptosis (TWEAK)
induces infl ammatory and proliferative effects in human kidney
cells. Cytokine 2009; 46: 24-35
12. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J,
Benjamin CB, Ambrose C, Dayer JM: Proinfl ammatory activity of
TWEAK on human dermal fi broblasts and synoviocytes: Blocking
and enhancing effects of anti-TWEAK monoclonal antibodies.
Arthritis Res 2002; 4: 126-133
13. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J Lössner U, Blüher
M, Stumvoll M, Fasshauer M: Serum levels of the atherosclerosis
biomarkers TWEAK are decreased in type 2 diabetes and end-stage
renal disease. Atherosclerosis 2008; 199: 440-444
14. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J,
Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J: Identifi cation
of soluble tumor necrosis factor-like weak inducer of apoptosis
(sTWEAK) as a possible biomarker of subclinical atherosclerosis.
Arterioscler Thromb Vasc Biol 2007; 27: 916-922
15. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A,
Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM:
Soluble TWEAK plasma levels as a novel biomarker of endothelial
function in patients with chronic kidney disease. Clin J Am Soc
Nephrol 2009; 4: 1716-1723
16. Carrero JJ, Ortiz A, Qureshi AR, Barany P, Heimbürger O, Marrón
B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-
Colio LM: Additive effects of soluble TWEAK and infl ammation
on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;
4: 110-118
17. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim
CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell
T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS,
Liao R, Burkly LC: A novel role for tumor necrosis factor-like
weak inducer of apoptosis (TWEAK) in the development of cardiac
dysfunction and failure. Circulation 2009; 119: 2058-2068
18. Gungor O, Kircelli F, Asci G, Carrero JJ, Tatar E, Demirci MS,
Ozbek SS, Ceylan N, Toz H, Ozkahya M, Ok E: Soluble TWEAK
level: Is it a marker for cardiovascular disease in long-term
hemodialysis patients? J Nephrol 2012 Apr 13:0
19. Gungor O, Kismali E, Sisman AR, Kircelli F, Carrero JJ, Tatar E,
Asci G, Toz H: The Relationships between Serum sTWEAK, FGF-
23 Levels, and Carotid Atherosclerosis in Renal Transplant Patients.
Ren Fail 2013; 35(1): 77-81
Thank you for copying data from http://www.arastirmax.com
